Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, John G. Gribben et al.|New England Journal of Medicine|2023Cited by 155
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Andrés J.M. Ferreri, Christopher P. Fox et al.|British Journal of Haematology|2020Cited by 69
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryMatthew R. Wilson, Pam McKay, Toby A. Eyre et al.|Blood Advances|2020Cited by 54
Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndrés J.M. Ferreri, M. Dreyling, Gerald Illerhaus et al.|Annals of Oncology|2024Cited by 46
Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐upAndrés J. M. Ferreri, Martin Dreyling, Jeanette K. Doorduijn et al.|HemaSphere|2024Cited by 26